Biodesix To Present New INSIGHT Study Data At ASCO 2025 Showing VeriStrat Test Predicts Improved Survival With Chemoimmunotherapy Over Immunotherapy Alone In PD-L1 ≥50% Metastatic NSCLC Patients With Poor Immune Classifier

Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled "Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC" features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone's Perlmutter Cancer Center.

The VeriStrat test measures a patient's immune response to lung cancer and is reported as either Host Immune Classifier Hot (VeriStrat Good) or Host Immune Classifier Cold (VeriStrat Poor). The new data strengthens prior findings and demonstrates statistically significant improvement of overall survival (OS) in patients with a VeriStrat Poor result when receiving immunotherapy combined with chemotherapy versus immunotherapy as a single agent. Notably, the two-year survival rate was more than three times higher in patients receiving immunotherapy plus chemotherapy compared to those who received immunotherapy alone. Additionally, patients with a VeriStrat Good result had comparable survival when receiving either treatment regimen.